Heart, Lung and Circulation

Totally Percutaneous Transfemoral Transcatheter Aortic Valve Replacement Despite Failure to Deploy a Vascular Closure Device: A Single-Centre Case Series

Published:October 01, 2021DOI:


      Transcatheter aortic valve replacement (TAVR) is preferably performed as a completely percutaneous procedure via transfemoral access. Suture-mediated vascular closure devices are deployed prior to sheath insertion (pre-closure). Inability to perform pre-closure may necessitate surgical vascular repair of the femoral artery. Patients at increased risk of vascular surgery complications may benefit from a percutaneous method for achieving access site haemostasis. Stent graft implantation is commonly used for treating access site injury following TAVR. This study assessed the feasibility of a strategy of planned stent graft implantation within the femoral artery for achieving access site haemostasis in patients undergoing transfemoral TAVR and in whom vascular pre-closure was not possible.


      A prospective institutional TAVR registry was retrospectively analysed and a cohort of patients were identified who were selected for transfemoral valve delivery and in whom pre-closure failed and access site haemostasis was achieved by stent graft implantation.


      This strategy was used for achieving access site haemostasis in 11 patients (1.5% of 744 patients undergoing transfemoral TAVR). These patients were considered to be at increased risk of vascular surgery complications due to advanced age, frailty, comorbidities, or immobility. Stent graft implantation achieved access site haemostasis in all patients. During follow-up, 30-day mortality was zero, 1-year mortality was 27%, and none of the patients required additional vascular interventions.


      The preliminary data suggest that planned stent graft implantation within the femoral artery may achieve access site haemostasis and enable a totally percutaneous TAVR procedure, despite failure to perform pre-closure with a suture-based vascular closure device.


      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Heart, Lung and Circulation
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Cahill T.J.
        • Chen M.
        • Hayashida K.
        • Latib A.
        • Modine T.
        • Piazza N.
        • et al.
        Transcatheter aortic valve implantation: current status and future perspectives.
        Eur Heart J. 2018; 39: 2625-2634
        • Segal A.
        • Flugelman M.Y.
        • Khader N.
        • Rubinshtein R.
        • Lavi I.
        • Karmeli R.
        • et al.
        Outcome of stent graft implantation for treatment of access site bleeding after transfemoral transcatheter aortic valve replacement.
        Am J Cardiol. 2017; 120: 456-460
        • Sedaghat A.
        • Hansen K.L.
        • Schahab N.
        • May M.C.
        • Weber M.
        • Stundl A.
        • et al.
        Long-term follow-up after stent graft placement for access-site and access-related vascular injury during TAVR-the Bonn-Copenhagen experience.
        Int J Cardiol. 2019; 281: 42-46
        • Steinvil A.
        • Bernardo N.
        • Rogers T.
        • Koifman E.
        • Buchanan K.
        • Alraies M.C.
        • et al.
        Use of an ePTFE-covered nitinol self-expanding stent graft for the treatment off pre-closure device failure during transcatheter aortic valve replacement.
        Cardiovasc Revasc Med. 2017; 18: 128-132
        • De Backer O.
        • Arnous S.
        • Sandholt B.
        • Brooks M.
        • Biasco L.
        • Franzen O.
        • et al.
        Safety and efficacy of using the Viabahn endoprosthesis for percutaneous treatment of vascular access complications after transfemoral aortic valve implantation.
        Am J Cardiol. 2015; 115: 1123-1129
        • Schneider D.B.
        • Krajcer Z.
        • Bonafede M.
        • Thoma E.
        • Hasegawa J.
        • Bhounsule P.
        • et al.
        Clinical and economic outcomes of proglide compared with surgical repair of large bore arterial access.
        J Comp Eff Res. 2019; 8: 1381-1392
        • Vierhout B.P.
        • Pol R.A.
        • El Moumni M.
        • Zeebregts C.J.
        Arteriotomy closure devices in EVAR, TEVAR, and TAVR: a systematic review and meta-analysis of randomised clinical trials and cohort studies.
        Eur J Vasc Endovasc Surg. 2017; 54: 104-115
        • Drafts B.C.
        • Choi C.H.
        • Sangal K.
        • Cammarata M.W.
        • Applegate R.A.
        • Gandhi S.K.
        • et al.
        Comparison of outcomes with surgical cut-down versus percutaneous transfemoral transcatheter aortic valve replacement: TAVR transfemoral access comparisons between surgical cut-down and percutaneous approach.
        Catheter Cardiovasc Interv. 2018; 91: 1354-1362
        • Chen I.M.
        • Lee T.H.
        • Chen P.L.
        • Shih C.C.
        • Chang H.H.
        Factors in proglide(r) vascular closure failure in sheath arteriotomies greater than 16 French.
        Eur J Vasc Endovasc Surg. 2019; 58: 615-622
        • Lee C.H.
        • Ko Y.G.
        • Park Y.
        • Shim C.Y.
        • Hong G.R.
        • Lee S.H.
        • et al.
        Risk factors for closure failure following percutaneous transfemoral transcatheter aortic valve implantation.
        Ann Vasc Surg. 2020; 66: 406-414
        • Batchelor W.
        • Patel K.
        • Hurt J.
        • Totten J.
        • Burroughs P.
        • Smith G.
        • et al.
        Incidence, prognosis and predictors of major vascular complications and percutaneous closure device failure following contemporary percutaneous transfemoral transcatheter aortic valve replacement.
        Cardiovasc Revasc Med. 2020; 21: 1065-1073
        • Rymer J.A.
        • Xiang Q.
        • Wang A.
        • Cohen D.J.
        • Desai N.D.
        • Kirtane A.J.
        • et al.
        Factors associated with and outcomes of aborted procedures during elective transcatheter aortic valve replacement.
        JACC Cardiovasc Interv. 2019; 12: 1768-1777
        • Otto C.M.
        • Kumbhani D.J.
        • Alexander K.P.
        • Calhoon J.H.
        • Desai M.Y.
        • Kaul S.
        • et al.
        2017 ACC expert consensus decision pathway for transcatheter aortic valve replacement in the management of adults with aortic stenosis: a report of the American College of Cardiology task force on clinical expert consensus documents.
        J Am Coll Cardiol. 2017; 69: 1313-1346
        • Witberg G.
        • Tzalamouras V.
        • Adams H.
        • Patterson T.
        • Roberts-Thomson R.
        • Byrne J.
        • et al.
        Routine ultrasound or fluoroscopy use and risk of vascular/bleeding complications after transfemoral TAVR.
        JACC Cardiovasc Interv. 2020; 13: 1460-1468